Recent systematic literature reviews concluded that the superiority of combined anti-CTLA-4 and anti-PD-1 therapy for melanoma and NSCLC in the response rates or OS has been proven to date, which is contrary to our conclusion (p = 0.32 and p = 0.1) [67,68]. Here, PDCD1 is linked to melanoma.